proteomic and metabolomic strategies to investigate hiv-associated neurocognitive disorders蛋白质组学和代谢组学策略调查艾滋病神经认知障碍.pdfVIP

Pendyala and Fox Genome Medicine 2010, 2:22 /content/2/3/22 RE VIE W Proteomic and metabolomic strategies to investigate HIV-associated neurocognitive disorders Gurudutt Pendyala and Howard S Fox* cognitive motor disorder and the most severe disease, Abstract HIV-1-associated dementia (HAD) [3]. Diagnosing neurodegenerative diseases, monitoring e advent of combined antiretroviral therapy (cART; their progression and assessing responses to previously referred to as highly active antiretroviral treatments will all be aided by the identication of therapy, HAART), however, has significantly changed the molecular markers of dierent stages of pathology. dynamics of HIV neuropathogenesis [4]. Severe dementia Protein biomarkers for HIV-associated neurocognitive now affects less than 7% of infected people during the disorders that have been discovered using proteomics latter stages of disease. Because of the increasing longe- include complement C3, soluble superoxide dismutase vity of HIV-1-infected individuals, the incidence of HAD, and a prostaglandin synthase. Metabolomics has not as well as the other cognitive and motor abnormalities yet been widely used for biomarker discovery, but early associated with HIV-1 infection, has declined, although work shows that it has great potential. the overall prevalence of neuroAIDS has increased [1,3,5-7]. e most severe cognitive, motor and behavioral impair-